Editorial Comment to Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors

Int J Urol. 2022 Jul;29(7):747. doi: 10.1111/iju.14949. Epub 2022 May 31.

Authors

Finn-Ole Paulsen¹, Christoph Seidel¹

Affiliation

¹ Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

PMID: 35640915
DOI: 10.1111/iju.14949

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use
Biomarkers
Clinical Trials, Phase II as Topic
Humans
Neoplasms, Germ Cell and Embryonal* / diagnosis
Neoplasms, Germ Cell and Embryonal* / drug therapy
Nivolumab* / therapeutic use

Substances

Antineoplastic Agents, Immunological
Biomarkers
Nivolumab